Long-term renal preservation in essential hypertension : Angiotensin converting enzyme inhibition is superior to β-blockade

Antihypertensive treatment is known to slow down the decline in glomerular filtration rate (GFR) with time. Angiotensin converting enzyme (ACE) inhibition has been shown to be more effective in this regard than conventional antihypertensive therapy. In a recent prospective, randomized, double blind trial in 257 patients with essential hypertension, the loss of GRF, determined with 51Cr-EDTA clearance, was significantly less with an ACE inhibitor (cilazapril) than with a β-adrenoceptor blocker (atenolol) during the first year of treatment. However, after 2 years, the two therapies were equally effective in this regard, thereby creating doubts about the long-term superiority of ACE inhibition in this regard. In order to elucidate whether the superior renal preservation with the ACE inhibitor was a transient effect, GFR was measured after 1 more year of treatment, ie, after 36 months. At that time, the decline in GFR was significantly smaller in the ACE inhibitor group as compared to the β-adrenoceptor blocker group (−3.0 [−5.5, −1.0; 95% CI] ν−7.0 [−9.0, −4.5; 95% CI] mL/min × 1.73 m2; P = .026). This demonstrates that in the treatment of essential hypertension ACE inhibition preserves GFR significantly better than β-adrenoceptor blockade during long-term therapy.